Andrew Nyborg

Andrew Nyborg has a diverse work experience in translational science and biology research. Andrew began their career in 2003 as an Antibody Design and Characterization Consultant for Abcam. In 2005, they became an Assistant Professor and Associate Consultant at the Mayo Clinic College of Medicine, where they developed novel mouse and rat models to explore mechanisms of neurodegenerative diseases. In 2007, they joined Adlyfe Inc. as a Senior Scientist, where they led the development of novel assays and methods and managed outside collaborations to preclinically develop an in vivo imaging agent. In 2008, they were a Senior Scientist at Virion Systems Inc., where they led efforts to develop in vivo and in vitro bioassay development for CD4/CD8 T-cell activity and proposed and developed novel cotton rat models of human viral infection and bacterial colonization. In 2009, they joined Fina Biosolutions LLC as a Scientific Advisory Board. In 2010, they joined MedImmune as a Principal Scientist, Infectious Disease & Vaccines Translational Medicine, and later as a Senior Scientist and Scientist II at BioSuperiors. In 2018, they joined Horizon as an Executive Director of Research and Senior Director of Development Sciences. Most recently, in 2022, they became the Vice President of Translational Science and Biology Research at ACELYRIN, INC.

Andrew Nyborg has a comprehensive educational background. Andrew began their studies at Boise State University, where they obtained a BS in Chemistry in 1996. Andrew then went on to pursue a PhD in Biochemistry at Brigham Young University, which they completed in 2000. Afterward, they became a Postdoctoral Fellow in Neuroscience, Neurodegeneration, and Molecular and Cell Biology at Mayo Clinic School of Medicine, which they completed in 2005.